

UKMF Spring Day

Assessment of disease response CR and beyond



Thursday 19th March 2015

Brunei Gallery, School of Oriental and African Studies, Thornhaugh Street, London WC1H 0XG

09.00 *Registration*

09.30 MRD assessments by flow

Dr Roger Owen

Leeds Teaching Hospitals

10.00 Minimal residual disease in multiple myeloma by next generation sequencing

Dr Ramon Garcia Sanz

University Hospital of Salamanca Spain

10.30 Paraproteins and response assessments – what have we learnt from MRC trials?

Professor Mark Drayson

University of Birmingham

11.00 *Coffee*

11.30 RAS pathways in myeloma

Dr Martin Kaiser

The Institute of Cancer Research

12.15 Cyclin and PI3K pathways

Professor Kwee Yong

University College London Hospitals

13.00 *Lunch*

14.00 **Michael Morley Lecture:**
Genomics guided therapy for myeloma

Professor Keith Stewart

Mayo Clinic, Scottsdale, Arizona

15.00 *Coffee*

15.20 ASH bursary winners

15.20 Flow-cytometric quantification of minimal residual disease (MRD) in myeloma: independent outcome prediction & sequential survival benefits per log tumour reduction

Dr Andy Rawstron

St James's Institute of Oncology

15.40 The extent of intra-clonal genetic diversity within the myeloma clone is a predictive biomarker of progression and outcome after treatment

Dr Lorenzo Melchor

The Institute of Cancer Research

16.00 Histone demethylase inhibition as a novel therapeutic strategy in myeloma

Dr Charlotte Pawlyn

The Institute of Cancer Research

16.20 Assessing MRD status following induction therapy, initial results of the PADIMAC phase 2 trial

Dr Rakesh Popat

University College London Hospitals

16.40 Questions

16.50 *Close*

Registration Fee: £60 (£40 for Scientists and Nurses)

For online registration please visit www.hartleytaylor.co.uk

For further information please email ukmf@hartleytaylor.co.uk or telephone 01296 584172 / 07900 634948

The following companies have supported the meeting by purchasing exhibition stand space and delegate places but have had no input into the programme, selection of speakers or topics:

Takeda, Binding Site, Janssen, Napp, Amgen, Celgene, Novartis, Chugai, Abingdon Health, Bristol Myers Squibb